
## CLAIMS

1. An antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs), wherein the one or more PBDs is/are:




PBD 5 .

2. The antibody drug conjugate of claim 1, wherein the linker comprises a cleavable linker.

3. The antibody drug conjugate of claim 2, wherein the cleavable linker comprises a peptidyl linker comprising at least two amino acids.

4. The antibody drug conjugate of claim 3, wherein the peptidyl linker comprises a valine-alanine dipeptide.

5. The antibody drug conjugate of claim 4 comprising the structure:



wherein the asterisk indicates the point of attachment to the one or more PBDs, and wherein the wavy line indicates the point of attachment to the remaining portion of the linker.


6. The antibody drug conjugate of claim 5, wherein the linker further comprises a maleimide group.

7. The antibody drug conjugate of claim 1, wherein the anti-DLL3 antibody is covalently linked to more than one PBD.

8. The antibody drug conjugate of claim 1, wherein the ADC has a drug loading of 2.

9. The antibody drug conjugate of claim 1, wherein 1 to 8 PBDs are covalently attached to the anti-DLL3 antibody.

10. The antibody drug conjugate according to claim 1, wherein the antibody drug conjugate comprises




**ADC 5,**

wherein Ab comprises the anti-DLL3 antibody.

11. The antibody drug conjugate according to claim 10, wherein Ab is covalently linked to more than one PBD.

12. The antibody drug conjugate according to claim 10, wherein the ADC has a drug loading of 2.

13. The antibody drug conjugate according to claim 10, wherein 1 to 8 PBDs are covalently attached to Ab.

14. The antibody drug conjugate of claim 1, wherein the anti-DLL3 antibody is selected from the group consisting of monoclonal antibody, chimeric antibody, CDR-grafted antibody, humanized antibody, human antibody, primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, diabody, Fab fragment, $F(ab')_2$ fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof.

15. The antibody drug conjugate of claim 1, wherein the anti-DLL3 antibody is an internalizing antibody.

16. The antibody drug conjugate of claim 1, wherein the anti-DLL3 antibody specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 1 or 2.

17. The antibody drug conjugate of claim 16, wherein the anti-DLL3 antibody specifically binds to an epitope comprising amino acids G203, R205, and P206 (SEQ ID NO:4).

18. The antibody drug conjugate of claim 1, wherein the anti-DLL3 antibody competes for binding to a human DLL3 protein with an antibody comprising a light chain variable region set forth as SEQ ID NO: 405 and a heavy chain variable region set forth as SEQ ID NO: 407.

19. The antibody drug conjugate of claim 18, wherein the anti-DLL3 antibody comprises three CDRs of a light chain variable region set forth as SEQ ID NO: 405 and three CDRs of a heavy chain variable region set forth as SEQ ID NO: 407.

20. The antibody drug conjugate of claim 19, wherein the anti-DLL3 antibody comprises residues 24-34 of SEQ ID NO: 405 for CDR-L1, residues 50-56 of SEQ ID NO: 405 for CDR-L2, residues 89-97 of SEQ ID NO: 405 for CDR-L3, residues 31-35 of SEQ ID NO: 407 for CDR-H1, residues 50-65 of SEQ ID NO: 407 for CDR-H2, and residues 95-102 of SEQ ID NO: 407 for CDR-H3, wherein the residues are numbered according to Kabat.

21. The antibody drug conjugate of claim 18, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407.

22. A pharmaceutical composition comprising (a) the antibody drug conjugate of claim 1, and (b) a pharmaceutically acceptable carrier.

23. The pharmaceutical composition of claim 22 comprising a drug to antibody ratio (DAR) of 1, 2, 3, 4, 5, 6, 7 or 8 each +/- 0.4.


24. The pharmaceutical composition of claim 23 comprising a DAR of 2 +/- 0.4.

25. The pharmaceutical composition of claim 24 comprising less than 30% of non-predominant ADC species.

26. An antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs),

wherein the anti-DLL3 antibody comprises three CDRs of a light chain variable region set forth as SEQ ID NO: 405 and three CDRs of a heavy chain variable region set forth as SEQ ID NO: 407; and

wherein the one or more PBDs is/are:




PBD 5 .

27. The antibody drug conjugate of claim 26, wherein the anti-DLL3 antibody comprises residues 24-34 of SEQ ID NO: 405 for CDR-L1, residues 50-56 of SEQ ID NO: 405 for CDR-L2, residues 89-97 of SEQ ID NO: 405 for CDR-L3, residues 31-35 of SEQ ID NO: 407 for CDR-H1, residues 50-65 of SEQ ID NO: 407 for CDR-H2, and residues 95-102 of SEQ ID NO: 407 for CDR-H3, wherein the residues are numbered according to Kabat.

28. The antibody drug conjugate of claim 27, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407.

29. The antibody drug conjugate of claim 28, wherein the linker comprises a valine-alanine dipeptide.

30. The antibody drug conjugate of claim 29 comprising the structure:



wherein the asterisk indicates the point of attachment to the one or more PBDs, and wherein the wavy line indicates the point of attachment to the remaining portion of the linker.

31. The antibody drug conjugate of claim 26, wherein the anti-DLL3 antibody is covalently linked to more than one PBD.

32. The antibody drug conjugate of claim 26, wherein the ADC has a drug loading of 2.

33. The antibody drug conjugate of claim 26, wherein 1 to 8 PBDs are covalently attached to the anti-DLL3 antibody.

34. A pharmaceutical composition comprising (a) the antibody drug conjugate of claim 26, and (b) a pharmaceutically acceptable carrier.

35. The pharmaceutical composition of claim 34 comprising a drug to antibody ratio (DAR) of 1, 2, 3, 4, 5, 6, 7 or 8 each +/- 0.4.


36. The pharmaceutical composition of claim 35 comprising a DAR of 2 +/- 0.4.

37. The pharmaceutical composition of claim 36 comprising less than 30% of non-predominant ADC species.

38. An antibody drug conjugate (ADC) comprising an anti-DLL3 antibody covalently linked through a linker to one or more pyrrolobenzodiazepines (PBDs),

wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407;

wherein the one or more PBDs is/are:




PBD 5 ; and

wherein the ADC has a drug loading of 2.

39. The antibody drug conjugate of claim 38, wherein the linker comprises a valine-alanine dipeptide.

40. The antibody drug conjugate of claim 39 comprising the structure:




wherein the asterisk indicates the point of attachment to the one or more PBDs, and wherein the wavy line indicates the point of attachment to the remaining portion of the linker.

41. A pharmaceutical composition comprising (a) the antibody drug conjugate of claim 40, and (b) a pharmaceutically acceptable carrier.

42. The pharmaceutical composition of claim 41 comprising a DAR of 2 +/- 0.4.

43. The pharmaceutical composition of claim 42 comprising less than 30% of non-predominant ADC species.

44. An antibody drug conjugate (ADC) comprising:




**ADC 5**,

wherein Ab comprises an anti-DLL3 antibody comprising three CDRs of a light chain variable region set forth as SEQ ID NO: 405 and three CDRs of a heavy chain variable region set forth as SEQ ID NO: 407.

45. The antibody drug conjugate of claim 44, wherein the anti-DLL3 antibody comprises residues 24-34 of SEQ ID NO: 405 for CDR-L1, residues 50-56 of SEQ ID NO: 405 for CDR-L2, residues 89-97 of SEQ ID NO: 405 for CDR-L3, residues 31-35 of SEQ ID NO: 407 for CDR-H1, residues 50-65 of SEQ ID NO: 407 for CDR-H2, and residues 95-102 of SEQ ID NO: 407 for CDR-H3, wherein the residues are numbered according to Kabat.

46. The antibody drug conjugate of claim 44, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407.

47. The antibody drug conjugate according to claim 44, wherein Ab is covalently linked to more than one PBD.

48. The antibody drug conjugate according to claim 44, wherein the ADC has a drug loading of 2.

49. The antibody drug conjugate according to claim 44, wherein 1 to 8 PBDs are covalently attached to Ab.


50. A pharmaceutical composition comprising (a) the antibody drug conjugate of claim 44, and (b) a pharmaceutically acceptable carrier.

51. The pharmaceutical composition of claim 50 comprising a drug to antibody ratio (DAR) of 1, 2, 3, 4, 5, 6, 7 or 8 each +/- 0.4.

52. The pharmaceutical composition of claim 51 comprising a DAR of 2 +/- 0.4.

53. The pharmaceutical composition of claim 52 comprising less than 30% of non-predominant ADC species.

54. An antibody drug conjugate (ADC) comprising:




**ADC 5**;

wherein Ab comprises an anti-DLL3 antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 407; and

wherein the ADC has a drug loading of 2.

55. A pharmaceutical composition comprising (a) the antibody drug conjugate of claim 54, and (b) a pharmaceutically acceptable carrier.

56. The pharmaceutical composition of claim 55 comprising a DAR of 2 +/- 0.4.

57. The pharmaceutical composition of claim 56 comprising less than 30% of non-predominant ADC species.

58. The pharmaceutical composition of claim 55 comprising a DAR of 2 +/- 0.3.

59. The pharmaceutical composition of claim 58 comprising less than 30% of non-predominant ADC species.